ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
117.96
+2.33 (+2.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close115.63
Open115.24
Bid0.00 x 900
Ask121.00 x 1000
Day's Range112.73 - 118.79
52 Week Range65.81 - 125.72
Volume588,556
Avg. Volume714,470
Market Cap13.151B
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-7.71
Earnings DateFeb 04, 2020 - Feb 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est135.00
  • Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 46%?
    Simply Wall St.

    Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 46%?

    Does the January share price for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reflect what it's really worth? Today, we...

  • Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure
    American City Business Journals

    Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure

    With competition encroaching, Alexion executives are pushing plans to more than double the company’s product portfolio in the next three years, including at least one “high risk, high reward” drug candidate.

  • Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
    Zacks

    Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

    Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

  • Business Wire

    Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2019 global net product revenues for ONPATTRO and GIVLAARI and provided additional updates on the products’ commercial launches.

  • Business Wire

    Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1 (PH1). The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-clinical components to the FDA and expects to submit the remaining components in early 2020. Alnylam also announced that it has been granted a pediatric rare disease designation from the FDA for lumasiran for the treatment of PH1.

  • Cambridge startup raises $110M for re-doseable gene therapies
    American City Business Journals

    Cambridge startup raises $110M for re-doseable gene therapies

    One of Cambridge’s emerging gene therapy startups has raised $110 million to support the company as it heads toward in-human trials. Generation Bio closed the Series C round this week, bringing in new investors T. Rowe Price, Farallon and Wellington Management, as well as previous backers Atlas Venture, Fidelity and others. The Series C round brings the total money raised by Generation Bio to more than $235 million.

  • American City Business Journals

    Biogen signs neuro disease drug deal with Cambridge startup

    A young biotech startup hoping to map out the actions of cells throughout the body has signed its second major drug development partner with biotech giant Biogen.

  • How Did Alnylam Pharmaceuticals, Inc. (ALNY) Compare Against Top Hedge Fund Stocks in 2019?
    Insider Monkey

    How Did Alnylam Pharmaceuticals, Inc. (ALNY) Compare Against Top Hedge Fund Stocks in 2019?

    It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]

  • These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen
    TipRanks

    These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen

    The calendar might have flipped to 2020, but that doesn’t mean everything has changed. Investors are still scouring the Street in search of the most compelling investment opportunities, the names that could see 2020 be their year.These aren’t just any run of the mill stocks. We’re talking about tickers that are set to outperform the broader market and can hand over substantial returns in the year ahead. Having said that, tackling this job isn’t always easy. With so many options out there, it can seem overwhelming. Luckily, Wall Street analysts are here to lend a hand.Often experts in the industries that they cover, a nod of approval from the Street’s seasoned pros can signal that a certain stock should be on investors’ radar. Bearing this in mind, we turned to the analysts at investing firm Cowen for some inspiration as we started our own search. Using TipRanks, which assembles a comprehensive database of stock performance information, we were able to take a closer look at 3 of the firm’s top picks for 2020. To top it off, each has the support of the rest of the Street as well, boasting a “Strong Buy” consensus rating.Alexion Pharmaceuticals (ALXN)Alexion is best known for developing innovative therapies to improve the lives of patients battling rare diseases. While the company stumbled a bit in 2019 as a result of concerns about competition from biosimilars, Cowen thinks that 2020 could see a major turnaround for the company.Analyst Phil Nadeau tells investors that the market has been “overly harsh” about ALXN’s potential, noting that the shift from its Soliris drug to Ultomiris should bode well for the company. “Our DCF analysis suggests that the current stock price assumes that worldwide sales of ALXN’s C5 franchise in atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) in 2024 and after are 75% below our current projections. We think that this is an overly pessimistic view of its sustainability. Based on Ultomiris' benefits over Soliris we think that ALXN's franchise is far more defensible than most investors give it credit,” he explained.According to Nadeau, the fact that ALXN has made significant progress in terms of rebuilding its pipeline and transferring the C5 franchise to Ultomiris could drive a re-rating for the healthcare name. Not only does Ultomiris offer improved potency and convenience, but it also has a lower annual price. Additionally, the maturation of its pipeline could contribute to gains in 2020.As a result, the five-star analyst left the Outperform rating and $165 price target as is. At this target, shares could climb 55% in the twelve months ahead. (To watch Nadeau’s track record, click here)What does the rest of the Street have to say? As it turns out, Wall Street is also in favor of ALXN. 12 Buy ratings and 3 Holds received in the last three months make it a Strong Buy. While lower than Nadeau’s estimate, the $145.67 average price target puts the upside potential at a respectable 37%. (See Alexion stock analysis on TipRanks)Alnylam Pharmaceuticals (ALNY)Using RNA interference (RNAi), Alnylam is changing the way debilitating diseases are treated. Based on the Nobel Prize-winning science, the company offers five late-stage programs that could address the large unmet need. Even with shares up 58% in the last year, Cowen’s Ritu Baral believes even more gains are in store.The analyst cites ALNY’s patented GalNAc construct science as well as its clinical strategy as helping it become a “dominant” player in the space. Its ONPATTRO (patisiran) drug for hATTR familial amyloid polyneuropathy (FAP) has already impressed with its performance and has seen consistent growth since its initial launch. In its third quarter, sales came in at $46.1 million, up 21% quarter-over-quarter with 600 patients currently using the therapy. Part of this success is thanks to its partnerships with 23andMe and genetic testing through the Alnylam Act Program, which has increased physician education, disease awareness and helped improve diagnostic methodology.The good news doesn’t stop there in Baral’s opinion. “The company is further de-risked by its late-stage compounds including just-launched GIVLAARI, inclisiran, and lumasiran that should significantly increase recurrent revenues within the next 24-months and drive top-line growth. This is coupled with multiple early stage programs (most wholly owned, some partnered) in both orphan disorders and more prevalent diseases which should yield multiple catalysts in the same time frame,” the five-star analyst commented.Baral argues that the company is transitioning to a “self-sustainable large cap biotechnology”, with this potentially attracting a broader group of investors. It’s no wonder, then, that the analyst boosted the price target from $120 to $154 in addition to maintaining the Outperform rating. This conveys her confidence in ALNY’s ability to surge 33% in the next twelve months. (To watch Baral’s track record, click here)Similarly, the rest of the Street takes a bullish approach when it comes to ALNY. A Strong Buy consensus rating is broken down into 13 Buys, 1 Hold and 1 Sell. Based on the average price target of $136.47, the upside potential lands at 18%. (See Alnylam stock analysis on TipRanks)Argenx SE (ARGX)With a novel approach that combines the diversity of the llama immune system and antibody engineering, Argenx develops treatments for cancer and severe autoimmune diseases. On the heels of a stellar 2019, Cowen is expecting a similar performance to be slated for 2020.Analyst Yaron Werber highlights the company’s lead candidate efgartigimod (anti-FcRn antibody fragment) as having a “potentially best-in-class profile with a first mover advantage across several indications.” The drug is targeting lucrative multi-billion dollar markets, with his estimate putting peak sales at $2.3 billion.While there are treatment options currently available for autoimmune disorders like Myasthenia Gravis (MG), pemphigus vulgaris (PV), idiopathic thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) such as steroids and immunosuppressants, they aren’t always tolerated well and IVIg is expensive, inconvenient and faces capacity constraints. “Efgartigimod is the most advanced FcRn antagonist in development and we anticipate that positive data in PV (POC Ph2: H1:20) and MG (Ph3: H2:20) should drive stock appreciation,” Werber noted.In addition, the company has partnered with Johnson & Johnson, which could speed up the development of cusatuzumab, its anti-CD70 antibody currently in Phase 2.Werber added, “With a deep pipeline, multiple catalysts in FY20 and clear path for near- and longer-term value creation, the stock has ample room for appreciation based on data readouts, derisking clinical milestones, and boosting confidence in new indications.” To this end, Werber reiterated the Outperform rating while also attaching a new $191 price target. Should the five-star analyst’s target be met, shares are looking at a twelve-month gain of 20%. (To watch Werber’s track record, click here)In general, other Wall Street analysts are on the same page. With 10 Buys compared to a single Hold, the word on the Street is that ARGX is a Strong Buy. Given the $180.90 average price target, the upside potential amounts to 14%. (See Argenx stock analysis on TipRanks)

  • Business Wire

    Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 10:30 am PT (1:30 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2019 global net product revenues. In addition, the Company will webcast the Q&A breakout session immediately following its presentation at 11:00 am PT (2:00 pm ET).

  • We've made it to 2020. These are the top business issues to look for in the new year
    American City Business Journals

    We've made it to 2020. These are the top business issues to look for in the new year

    It's 2020 — do you have the vision it takes to grow your business in the new year? You have questions. We have answers. Where will cash-rich venture capital firms invest? Will New England, a higher education mecca, see additional closures and mergers of colleges and universities? What about potential treatments for cancer, rare diseases, and diabetes? Looking into the year ahead, Business Journal staffers asked the questions, and ferreted out some answers, and their potential impact on local business.

  • Alnylam Stock Up More Than 61% YTD on Pipeline Progress
    Zacks

    Alnylam Stock Up More Than 61% YTD on Pipeline Progress

    Shares of Alnylam (ALNY) rise on significant pipeline progress.

  • Barrons.com

    Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.

    About 72 different drugs for a liver disease known as NASH are in the pipeline. Companies like Novartis, Intercept Pharmaceuticals, Gilead Sciences, Novo Nordisk, and Eli Lilly are all contenders.

  • Benzinga

    10 Biotech M&A Targets Under The Scanner For 2020

    Biopharma M&A activity scaled record highs in 2019, with a few mega mergers announced involving names such as Bristol-Myers Squibb Co (NYSE: BMY ), Roche Holdings AG Basel ADR (OTC: RHHBY ) and AbbVie ...

  • Alnylam's Kidney Disease Drug Succeeds in Late Stage Study
    Zacks

    Alnylam's Kidney Disease Drug Succeeds in Late Stage Study

    Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.

  • Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally Fails
    Investor's Business Daily

    Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally Fails

    Shares of Alnylam Pharmaceuticals tried to rally Tuesday after the biotech company's RNAi technology succeeded in a kidney disease. But Alnylam has some rivals waiting in the winds.

  • MarketWatch

    Alnylam's shares rise on late-stage rare disease results

    Shares of Alnylam Pharmaceuticals Inc. are up 1% in morning trading on the news that lumasiran, its investigational rare disease therapy, met its primary endpoint in a Phase 3 trial. Alnylam is testing lumasiran as a treatment for primary hyperoxaluria type 1, a rare genetic kidney disorder. The company said it plans to submit the drug to the Food and Drug Administration and the European Medicines Agency early next year. Alnylam now expects to have four marketed products by the end of next year, CEO John Maraganore said in a news release. It currently has two approved products in the U.S.-Givlaari and Onpattro. Alnylam's stock has gained 68% year-to-date. The S&P 500 is up 27%.

  • Business Wire

    Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) in development for the treatment of primary hyperoxaluria type 1 (PH1), met its primary efficacy endpoint and all tested secondary endpoints. Specifically, lumasiran met the primary efficacy endpoint of percent change from baseline, relative to placebo, in 24-hour urinary oxalate excretion averaged across months 3 to 6 (p less than 0.0001). The study also achieved statistically significant results for all six tested secondary endpoints (p less than or equal to 0.001). Lumasiran also demonstrated an encouraging safety and tolerability profile. Based on these results, the Company plans to submit a New Drug Application (NDA) and file a Marketing Authorisation Application (MAA) for lumasiran in early 2020.

  • Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe
    Zacks

    Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe

    Pfizer (PFE) receives a positive CHMP opinion recommending approval for once-daily Vyndaqel (61mg) oral capsule to treat hereditary transthyretin amyloid cardiomyopathy in adult patients.

  • Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals (ALNY)
    Zacks

    Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals (ALNY)

    Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Alnylam (ALNY) Moves to Buy: Rationale Behind the Upgrade
    Zacks

    Alnylam (ALNY) Moves to Buy: Rationale Behind the Upgrade

    Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Zacks

    Guest Host Tonight

    Guest Host Tonight

  • Sanofi to restructure Newton diabetes startup Onduo, saying it 'over-invested'
    American City Business Journals

    Sanofi to restructure Newton diabetes startup Onduo, saying it 'over-invested'

    Sanofi’s new CEO laid out plans Tuesday to shake up one of the Bay State’s biggest drug companies, potentially throwing its 3-year-old diabetes-focused startup Onduo for a loop.

  • Trade of the 2020's: Sell Gold, Buy Biotech
    Zacks

    Trade of the 2020's: Sell Gold, Buy Biotech

    In 5 years, you be selling your gold and buying more companies leading the century of biology.